ANGPT1 and type 1 diabetes mellitus: Animal studies indicate that treatment with angiopoietin-1 might reduce kidney damage in unilateral ureteral obstruction, streptozotocin-induced type-1 diabetes, and folic acid induced nephropathy [15–17].